JAMA Pediatr:人类免疫缺陷病毒(HIV)在青少年中的感染情况

2017-07-19 qinqiyun MedSci原创

据估计,每年约有130万年龄在10-19岁的青少年死亡,其中大部分死因是可预防或可治疗的。可预防的死因主要是人类免疫缺陷病毒(HIV)感染。HIV是全球青少年死亡的主要原因之一,是非洲10-19岁青少年、全球10-24岁少女和年轻女性的首位死因。

全球年龄在10-24岁的青少年大约有18亿人,约占全球人口的四分之一。88%的青少年生活在中低收入水平的国家。保障这些青少年的健康对其成年后的情况、子代健康以及社会整体均长期有利。然而,关于青少年人群健康的调查研究发现饥荒仍然存在,特别是在中低收入国家。

据估计,每年约有130万年龄在10-19岁的青少年死亡,其中大部分死因是可预防或可治疗的。可预防的死因主要是人类免疫缺陷病毒(HIV)感染。HIV是全球青少年死亡的主要原因之一,是非洲10-19岁青少年、全球10-24岁少女和年轻女性的首位死因。

全球HIV患者中有三分之一是青少年,而且,感染HIV的青少年的死亡率没有像其他年龄段患者一样有所下降。青少年患者占全球新发HIV感染病例的一半,其中少女和年轻女性的感染情况不成比例。2015年在非洲撒哈拉沙漠以南地区,新增感染的15-19岁的青少年做四分之三是女性。

目前控制青少年HIV感染的进展不尽如人意,2009年后15-19岁人群中新发感染率才下降8%,而0-14岁儿童中感染率下降高达60%。如若我们还是不能控制HIIV在青少年中的感染情况,那么2050年时,非洲感染HIV的青少年将是现在的两倍。鉴于目前HIV的流行病学,社会应该优先倾注资源、研究和关注来预防HIV在青少年中的传播。

原始出处:

Lynne M.Mofenson.Preventing Human Immunodeficiency Virus Acquisition in Youth—Generations at Risk.JAMA Pediatr.July 17, 2017.doi:10.1001/jamapediatrics.2017.1702.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1637934, encodeId=d701163e93441, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 26 16:50:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726586, encodeId=a36f1e2658643, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 25 05:50:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651674, encodeId=175016516e432, content=<a href='/topic/show?id=26c125044e5' target=_blank style='color:#2F92EE;'>#人类免疫缺陷病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25044, encryptionId=26c125044e5, topicName=人类免疫缺陷病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091524239599, createdName=FukaiBao, createdTime=Sun Aug 20 14:50:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992320, encodeId=e89319923208d, content=<a href='/topic/show?id=71df2914104' target=_blank style='color:#2F92EE;'>#免疫缺陷病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29141, encryptionId=71df2914104, topicName=免疫缺陷病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Dec 06 07:50:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488962, encodeId=d69114889620a, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Thu Jul 20 23:50:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224159, encodeId=b896224159ee, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 20 08:02:47 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1637934, encodeId=d701163e93441, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 26 16:50:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726586, encodeId=a36f1e2658643, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 25 05:50:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651674, encodeId=175016516e432, content=<a href='/topic/show?id=26c125044e5' target=_blank style='color:#2F92EE;'>#人类免疫缺陷病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25044, encryptionId=26c125044e5, topicName=人类免疫缺陷病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091524239599, createdName=FukaiBao, createdTime=Sun Aug 20 14:50:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992320, encodeId=e89319923208d, content=<a href='/topic/show?id=71df2914104' target=_blank style='color:#2F92EE;'>#免疫缺陷病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29141, encryptionId=71df2914104, topicName=免疫缺陷病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Dec 06 07:50:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488962, encodeId=d69114889620a, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Thu Jul 20 23:50:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224159, encodeId=b896224159ee, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 20 08:02:47 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
    2017-08-25 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1637934, encodeId=d701163e93441, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 26 16:50:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726586, encodeId=a36f1e2658643, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 25 05:50:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651674, encodeId=175016516e432, content=<a href='/topic/show?id=26c125044e5' target=_blank style='color:#2F92EE;'>#人类免疫缺陷病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25044, encryptionId=26c125044e5, topicName=人类免疫缺陷病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091524239599, createdName=FukaiBao, createdTime=Sun Aug 20 14:50:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992320, encodeId=e89319923208d, content=<a href='/topic/show?id=71df2914104' target=_blank style='color:#2F92EE;'>#免疫缺陷病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29141, encryptionId=71df2914104, topicName=免疫缺陷病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Dec 06 07:50:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488962, encodeId=d69114889620a, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Thu Jul 20 23:50:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224159, encodeId=b896224159ee, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 20 08:02:47 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1637934, encodeId=d701163e93441, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 26 16:50:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726586, encodeId=a36f1e2658643, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 25 05:50:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651674, encodeId=175016516e432, content=<a href='/topic/show?id=26c125044e5' target=_blank style='color:#2F92EE;'>#人类免疫缺陷病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25044, encryptionId=26c125044e5, topicName=人类免疫缺陷病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091524239599, createdName=FukaiBao, createdTime=Sun Aug 20 14:50:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992320, encodeId=e89319923208d, content=<a href='/topic/show?id=71df2914104' target=_blank style='color:#2F92EE;'>#免疫缺陷病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29141, encryptionId=71df2914104, topicName=免疫缺陷病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Dec 06 07:50:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488962, encodeId=d69114889620a, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Thu Jul 20 23:50:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224159, encodeId=b896224159ee, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 20 08:02:47 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1637934, encodeId=d701163e93441, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 26 16:50:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726586, encodeId=a36f1e2658643, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 25 05:50:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651674, encodeId=175016516e432, content=<a href='/topic/show?id=26c125044e5' target=_blank style='color:#2F92EE;'>#人类免疫缺陷病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25044, encryptionId=26c125044e5, topicName=人类免疫缺陷病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091524239599, createdName=FukaiBao, createdTime=Sun Aug 20 14:50:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992320, encodeId=e89319923208d, content=<a href='/topic/show?id=71df2914104' target=_blank style='color:#2F92EE;'>#免疫缺陷病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29141, encryptionId=71df2914104, topicName=免疫缺陷病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Dec 06 07:50:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488962, encodeId=d69114889620a, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Thu Jul 20 23:50:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224159, encodeId=b896224159ee, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 20 08:02:47 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1637934, encodeId=d701163e93441, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Oct 26 16:50:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726586, encodeId=a36f1e2658643, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Aug 25 05:50:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651674, encodeId=175016516e432, content=<a href='/topic/show?id=26c125044e5' target=_blank style='color:#2F92EE;'>#人类免疫缺陷病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25044, encryptionId=26c125044e5, topicName=人类免疫缺陷病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091524239599, createdName=FukaiBao, createdTime=Sun Aug 20 14:50:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992320, encodeId=e89319923208d, content=<a href='/topic/show?id=71df2914104' target=_blank style='color:#2F92EE;'>#免疫缺陷病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29141, encryptionId=71df2914104, topicName=免疫缺陷病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Dec 06 07:50:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488962, encodeId=d69114889620a, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Thu Jul 20 23:50:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224159, encodeId=b896224159ee, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 20 08:02:47 CST 2017, time=2017-07-20, status=1, ipAttribution=)]
    2017-07-20 1dd8c52fm63(暂无匿称)

    学习学习

    0

相关资讯

EUR HEART J:青少年的体重与早期心脏衰竭风险之间的关系

研究发现,在正常体重已经可以检测到早期心衰的风险大大增加,并且在最高体重者中这一风险增加了近10倍。考虑到目前肥胖症的流行,未来年轻人的心脏衰竭可能会大幅度增加,医生们需要意识到这一点。

J Periodontol:不同的牙周检查方案对青少年牙龈出血与口腔健康相关生活质量的影响

目前还不清楚不同的口腔牙周检查(PMPE)方案如何影响牙龈出血(GB)与口腔健康相关的生活质量(OHRQoL)之间的关系的评估。 本研究的目的是评估不同PMPE对12岁青少年的GB和OHRQoL之间关系的影响。

J Rheumatol:尿液生物标记物能够预测儿童及青少年狼疮肾炎的治疗反应

基线时低水平的TGF-β、血浆铜蓝蛋白和第3个月时AGP、LPGDS,转铁蛋白、VDBP以及其他选择生物标志物的显著降低是LN缓解的突出预测指标。

J Hypertens:儿童和青少年种族和动脉僵硬度之间的相关性分析!

由此可见,该研究的结果表明黑人青春期高cf-PWV值较高,独立于血压值。因此,该研究的数据表明青春期是成人黑人血管轮廓出现的关键阶段。

Sci Rep:在青少年中,先天性耳聋与身体特异性性感觉缺失有关

听觉和触觉代表了两种不同的感官系统,两者都依赖于机械力量到电子信号的转化。最近,有研究人员利用一系列的定量感官测试来检测对照组青少年(14-20岁)和年龄匹配的具有先天性耳聋群体的探头接触、热效率和疼痛敏感度。感官测试在111名正常个体和36名具有先天性耳聋个体的优势手中进行。和对照组比较,患有先天耳聋的群体通过显著更高的震动检测阈值进行鉴定,10Hz(2倍增加,P<0.001)和125Hz

Lancet Child Adolescent Health:你在青春期“自虐”过吗?当心成年后变成“瘾君子”

近日,一篇发表在《柳叶刀》子刊“Lancet Child and Adolescent Health”上的文章揭示,青少年时期存在"自虐"倾向的群体在成年之后往往会出现社交障碍、焦虑以及药物上瘾等症状。 据悉,这项研究由默多克儿童研究所的研究者们记录了200名志愿者从14岁到35岁之间的相关数据。结果显示:1)青少年时期存在自虐行为的人群在35岁时吸食大麻的几率是同龄其它人群的2倍;2)在青少年